top of page
LATEST NEWS
Lexeo's One-Time Gene Therapy Cut Dangerous Heart Rhythms by 80% in PKP2 Heart Disease
Interim Phase I/II results for Lexeo's LX2020 show an 80% average drop in dangerous heart-rhythm runs at the higher dose, with heart biopsies showing the missing PKP2 protein restored. The FDA is open to a faster approval path.
4 hours ago3 min read


Every Gene Therapy Approval We've Covered: FDA Decisions 2025-2026
The FDA's list of approved gene therapies now stands at 33. Every approval and rejection Gene Tech Times has covered, and the pattern they show.
17 hours ago3 min read


CRISPR for Cholesterol and Triglycerides: Everything We've Covered
Gene editing is moving from rare disease to high cholesterol and high triglycerides. Every Gene Tech Times story on PCSK9 and ANGPTL3 editing, and the argument it starts.
17 hours ago3 min read


LEARN MORE
LEARN MORE

GENE TECH TIMES
The Future Has Arrived


Casgevy, the First CRISPR Medicine, Expands to Children as Young as 2
The FDA expanded Vertex's CRISPR therapy Casgevy to children aged 2 and older with sickle cell disease or transfusion-dependent beta-thalassemia. Here's how it works and why the approval for toddlers is notable.
Jul 29


Vertex’s Stem Cell Therapy: A Bold Leap Toward a Type I Diabetes Cure
Vertex Pharmaceuticals has announced a pivotal milestone for its VX-880 therapy, a stem-cell-derived islet cell treatment to restore insulin production in people with type 1 diabetes (T1D). The treatment, which previously underwent a Phase 1/2 clinical trial, is now entering a Phase 1/2/3 trial, making it the first scalable T1D cure to reach this advanced stage. This combined trial streamlines the research process, integrating safety, efficacy, and confirmatory studies into a
Jan 13, 2025


FDA Approves Stem Cell Therapy, Regenecyte, Shown to Help Chemotherapy Patients Recover Blood Count
The FDA has approved Regenecyte, an innovative therapy made from umbilical cord blood stem cells, to help rebuild blood and immune systems in patients with blood disorders or those recovering from intense treatments like chemotherapy. This breakthrough offers a promising option for patients needing healthy blood cell regeneration. Regenecyte uses stem cells collected from umbilical cords, which are highly adaptable and can grow into essential blood and immune cells. The treat
Nov 29, 2024
bottom of page


